You are here

Vyndaqel

Pfizer escapes proposed class action lawsuit over patient copay assistance

Fierce Pharma

Fri, 04/7/23 - 01:52 pm

copay asssistance programs

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication

Reuters

Tue, 01/10/23 - 10:59 am

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Fierce Pharma

Tue, 11/15/22 - 10:32 am

copay asssistance programs

Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

Fierce Pharma

Mon, 10/17/22 - 11:31 pm

Pfizer loses court battle to keep its Vyndaqel copay assistance for Medicare patients—again

Fierce Pharma

Tue, 07/26/22 - 05:23 pm

copay asssistance programs

Bridgebio sets its heart on besting Pfizer

EP Vantage

Fri, 12/3/21 - 10:31 am

transthyretin amyloid cardiomyopathy

Pfizer prohibited from subsidizing its heart drugs for Medicare patients

Beckers Hospital Review

Mon, 10/4/21 - 11:12 pm

Pfizer victory in Vyndaqel copay lawsuit could kneecap the government's only control on prices, lawyer warns

Fierce Pharma

Wed, 07/7/21 - 12:06 pm

Pfizer sues for U.S. permission to assist patients needing expensive heart drugs

Reuters

Fri, 06/26/20 - 07:45 pm

federal government

Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Fierce Pharma

Fri, 06/19/20 - 12:10 pm

Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

Fierce Biotech

Tue, 02/18/20 - 08:30 pm

transthyretin amyloidosis

Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs

Fierce Pharma

Tue, 01/28/20 - 11:34 pm

Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Motley Fool

Sat, 11/23/19 - 04:11 pm

Eidos Therapeutics

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

Motley Fool

Thu, 10/31/19 - 11:51 pm

Akcea Therapeutics

Ionis Pharmaceuticals

Eidos Therapeutics

Pfizer's heart drug impresses with fast US launch

Biopharma Dive

Tue, 10/29/19 - 10:50 pm

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Fierce Pharma

Fri, 10/18/19 - 07:45 pm

ATTR amyloidosis

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

Tue, 08/13/19 - 11:43 am

multiple sclerosis

metastatic bladder cancer

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Fierce Pharma

Thu, 05/30/19 - 12:36 pm

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Mon, 05/6/19 - 10:54 am

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

Motley Fool

Tue, 08/28/18 - 10:18 am

ATTR amyloidosis

Pages